Elutia Inc. Class A (ELUT)
NASDAQ: ELUTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ELUT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $39.96M
- EPS (TTM)
- -$0.68
- Dividend yield
- None
- 52-week range
- 0.50 – 1.39
- Day range
- 0.7908 – 0.9199
- Volume / Avg
- 83.28K / 185.17K
- Beta
- —
- Shares outstanding
- 44.40M
52-week range
ELUT stock today
Shares of Elutia (ELUT) finished higher on Nov 20 at $0.9001, a gain of 11.12% or $0.0901 per share, versus the S&P 500's 3.70% decline. Trading was light, with 83.28K shares changing hands, about 45% of the average daily volume. At this level, ELUT sits in the middle of its 52-week range of $0.50 to $1.39: 35.0% below the high, set on Mar 4, 2026 and 80.0% above the low.
ELUT is up 29.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 52.6%. Elutia has posted a net loss over the last twelve months (EPS of -$0.68), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Elutia
Company profileElutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications. The company operates in two segments, Women's Health and Cardiovascular. Its lead development programs include NXT-41 and NXT-41x, which are designed as biologic scaffolds combined with local antibiotic delivery.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. C. Randal Mills Ph.D.
- Headquarters
- Gaithersburg, MD
- Employees
- 25
- IPO year
- 2020
- Website
- elutia.com
Financial highlights
Full financialsIn fiscal 2025, Elutia generated $12.3 million in revenue, down 15.0% from fiscal 2024, its first annual decline since 2024. Net income was $53.4 million, for a net margin of 434.2% versus a median of -137.9% in the prior 5 years. Gross margin was 53.7% (up from 46.4%) and operating margin -218.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $12.29M | $14.47M | $24.75M | $23.85M | $47.39M |
| Growth | -15.03% | -41.54% | +3.76% | -49.68% | +11.03% |
| Net income | $53.38M | $-53.95M | $-37.66M | $-32.90M | $-24.83M |
| EPS (diluted) | $0.87 | $-1.86 | $-2.07 | $-2.38 | $-2.38 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$5.00+455.49%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.01 vs —
ELUT news
All ELUT news- Elutia Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Elutia Inc. Reports Third Quarter 2026 Results and Plans NXT-41x FDA SubmissionNasdaq
- Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through LaunchGlobeNewswire
- Elutia to Report Third Quarter 2026 Financial Results on Thursday, November 5, 2026GlobeNewswire
Elutia peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| INKTMiNK Therapeutics Inc. | 8.02 | -6.85% | $41.17M | vs ELUT |
| ELOXEloxx Pharmaceuticals Inc. | 10.69 | -1.75% | $43.69M | vs ELUT |
| GRMLGreenland Mines Ltd. | 2.99 | +2.75% | $44.31M | vs ELUT |
| TILInstil Bio Inc. | 5.23 | -5.77% | $35.47M | vs ELUT |
| IMAImageneBio Inc. | 3.92 | 0.00% | $48.83M | vs ELUT |
| CRBUCaribou Biosciences Inc. | 0.2843 | -8.44% | $30.71M | vs ELUT |
| KLRSKalaris Therapeutics Inc. | 1.28 | -5.19% | $30.47M | vs ELUT |
| EXOZeXoZymes Inc. | 2.91 | -14.05% | $27.42M | vs ELUT |
Indexes, lists and sector
Elutia stock FAQ
What is Elutia's stock price today?
ELUT last traded at $0.9001 as of Nov 20, 4:00 PM EST, up 11.12% on the day. Prices are delayed at least 15 minutes.
Who is Elutia's CEO?
Dr. C. Randal Mills Ph.D. is the chief executive officer of Elutia Inc. Class A, which has about 25 employees.
What is the ELUT 52-week high?
The 52-week high for ELUT is $1.39 and the 52-week low is $0.50. The stock is currently 35.0% below its high.